Low-dose blinatumomab for moderate to severe Sjögren's syndrome
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a low-dose medication called blinatumomab, which targets certain immune cells, to see if it can help control symptoms of moderate to severe Sjögren's syndrome, especially dry eyes. It is for people who have not gotten enough relief from standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of primary Sjögren's syndrome.
- Your disease must be moderate to severe, meaning your symptoms are not well controlled with standard treatments.
- You must have moderate to severe dry eye disease.
- You must have a positive anti-SSA antibody test (a blood test that supports the diagnosis).
- Your blood counts and organ function must be within safe limits (will be checked by the study team).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether upadacitinib, a pill that reduces inflammation, can help people with Sjögren's syndrome. It aims to see if the drug can lower disease activity and improve symptoms.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests an investigational drug called JH013 for primary Sjögren's syndrome. It aims to reduce dryness and other symptoms like fatigue and joint pain, and may help people with moderate to severe disease activity.
This study tests a new medicine called ESG206, which is designed to calm the immune system and reduce the symptoms of Sjögren's syndrome. If you join, you may get this medicine or a placebo, and the study will see if it safely helps with things like dry eyes and dry mouth.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
Hear when a new Primary Sjögren's Syndrome (pSS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.